Drugs / UNASNEMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05396235 | Aug → Dec 2022 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05240612 | May 2022 → Sep 2023 | tropical spastic paraparesis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04096950 | Apr 2020 → Jan 2021 | spinal cord injury | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04683848 | Aug 2021 → Dec 2024 | spinal cord injury | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UNASNEMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650492 ↗ |
| Known as | MT-3921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04096950 ↗ |
| Known as | rH116A3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650492 ↗ |
| Action | Inhibit | “Repulsive guidance molecule A inhibitor” CHEMBL4650492 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650492 ↗ |
| Route | Intravenous | “MT-3921 Low dose, intravenous, single dosing” NCT04096950 ↗ |
| Target | RGMA | “Repulsive guidance molecule A inhibitor” CHEMBL4650492 ↗ |